Siemens, Draws

Siemens Draws Divergent Analyst Calls as Healthineers Spin-Off Reshapes the Investment Case

Published on 11/20/2026 at 20:31 | Editorial boerse-global.de
Deutsche Bank lifts its Siemens price target to EUR 275 on the planned Healthineers spin-off, while AlphaValue/Baader cuts its target to EUR 253.
Siemens, Draws, Divergent, Analyst, Calls, Healthineers, Spin-Off, Reshapes, Investment, Case Illustration mit AI erstellt.

Deutsche Bank Research nudged its Siemens price target up to EUR 275 from EUR 270 on Monday while keeping a Hold rating, a modest revision that lands as the industrial group prepares to carve out its medical technology arm. Analyst Gael de-Bray reworked his valuation model to account for the planned separation of Siemens Healthineers, arguing the slimmed-down company could benefit from a tighter portfolio. That prospect alone, in the bank's view, does not justify a Buy.

The stock was under pressure in a weak European session, down 4.1% on the day.

Under the plan, the medical technology activities would be classified as a discontinued operation from the first quarter of fiscal 2027. Once the transaction closes, Deutsche Bank expects Siemens' revenue to fall by roughly 25%. Even so, the analysts take a constructive view of the smaller group: the remaining businesses should fit together better, and Siemens ought to be able to strengthen its hand in industrial artificial intelligence. What counts for valuation, they contend, is not simply how much revenue disappears but how well the leftover operations mesh.

The balance sheet would shift as well. Strip out the EUR 12 billion of Healthineers debt that would no longer sit on the group's books, and net liquidity would come to EUR 7.3 billion on Deutsche Bank's math. The bank puts the financial headroom for acquisitions at EUR 30 billion to EUR 40 billion — a window it frames as both an opportunity and a risk.

Should investors sell immediately? Or is it worth buying Siemens?

On adjusted earnings per share before purchase price allocation effects, Deutsche Bank models EUR 10.9 for fiscal 2027 excluding Healthineers, above Siemens' own guidance range of EUR 10.20 to EUR 10.80.

AlphaValue/Baader Europe moved in the opposite direction on the rating scale, lifting its recommendation from Sell to Reduce while trimming its target to EUR 253 from EUR 257. The two houses thus part ways on direction: Deutsche Bank now values Siemens more highly after the spin-off than before, while AlphaValue/Baader Europe has cut its mark.

Bernstein Research, for its part, reiterated an Outperform rating and left its EUR 330 target untouched in a note dated the previous day. Analyst Alasdair Leslie sees room for upward revisions to fiscal 2027 estimates, and he flagged the growing importance of industrial AI for Siemens' Digital Industries division. The shares were down 2.3% at the time of that report.

Siemens itself is guiding for comparable revenue growth of 9% to 11% in fiscal 2027, with earnings per share before purchase price allocation effects expected between EUR 10.20 and EUR 10.80. The company published its fiscal 2026 results on November 12: revenue came in at EUR 83.4 billion, up 8% on a comparable basis. Orders and free cash flow both set records, with order intake of EUR 108.2 billion and free cash flow of EUR 12.1 billion. For the year just ended, Siemens proposed a dividend of EUR 5.50 per share.

First-quarter fiscal 2027 figures are due on February 11, 2027.

Ad

Siemens Stock: New Analysis - 20 November

Fresh Siemens information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Siemens analysis...

Disclaimer...
en | DE0007236101 | SIEMENS | boerse | 70541039 |